To assess whether loss of RIPK3 could affect the response of malignant lymphoma cells to therapeutic agents we made use of CRISPR/Cas9 technology to generate Eμ-Myc p53 wild-type (AF47A and AH15A) lymphoma cell lines that are deficient for  RIPK3 (Supplementary Fig. 2a, b). This evidence concerns the gene MYC and lymphoma.